Online citations, reference lists, and bibliographies.
← Back to Search

Interim Results Of Pleurectomy/decortication And Intraoperative Intrapleural Hyperthermic Cisplatin Perfusion For Patients With Malignant Pleural Mesothelioma Intolerable To Extrapleural Pneumonectomy

H. Ishibashi, M. Kobayashi, C. Takasaki, K. Okubo
Published 2015 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
ObjectiveSurgical procedure for malignant pleural mesothelioma (MPM) remains controversial. We reviewed our protocol including pleurectomy/decortication (P/D) for patients with malignant pleural mesothelioma who were intolerable to extrapleural pneumonectomy (EPP).Patients and methodsFrom June 2010 to April 2014, 14 patients with MPM were intended to treat with multimodality therapy including surgery. Four patients who were intolerable to EPP received a protocol consisting of P/D and intraoperative intrapleural hyperthermic cisplatin perfusion, followed by systemic chemotherapy. Ten patients received trimodality treatment of EPP, systemic chemotherapy, and intensity modulated radiation therapy for hemithorax. Surgical outcomes of acute operative results and interim survivals were examined and compared between the groups.ResultsAll patients obtained macroscopic complete resection and received multimodality treatment in P/D and EPP groups. Operation time was longer in P/D group; however, there were no differences in ICU stays or hospitalizations. Four patients in P/D group and seven patients in EPP group experienced postoperative complications; however, there was no operative morality. EPP group suffered from cardiac complications and P/D group had prolonged airleak. Full walk recovery was obtained earlier in P/D group. One patient in P/D group had a local recurrence 11 months after surgery, while the other three patients survived 23–41 months with no evidence of diseases.ConclusionsP/D and intraoperative intrapleural cisplatin perfusion achieved a favorable macroscopic resection in patients with MPM who were intolerable to EPP. Postoperative complications were manageable and survival could be promising. Further study warrants with a larger number of patients.
This paper references
10.1200/JCO.2004.10.071
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2004)
10.1016/j.lungcan.2009.08.019
Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy.
S. Boeluekbas (2011)
10.1097/00000421-198212000-00014
Toxicity and response criteria of the Eastern Cooperative Oncology Group
M. Oken (1982)
10.1097/JTO.0b013e31824ab6c5
Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma
L. Lang-Lazdunski (2012)
[Survey of surgical treatment of malignant pleural mesothelioma in Japan].
M. Higashiyama (2007)
10.1183/09031936.00039510
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
10.1016/j.athoracsur.2012.02.009
Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma.
J. Friedberg (2012)
10.1016/S0360-3016(02)04151-2
Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma.
A. Ahamad (2003)
10.1016/j.jtcvs.2013.01.039
The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass.
V. Rusch (2013)
10.1200/JCO.2008.17.5604
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
10.1016/j.ejcts.2009.07.032
Three decades of experience in the surgical multi-modality management of pleural mesothelioma.
H. Luckraz (2010)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1016/S1010-7940(02)00273-7
The management of malignant pleural mesothelioma; single centre experience in 10 years.
T. Aziz (2002)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/j.jtcvs.2012.12.037
Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection.
D. Sugarbaker (2013)
10.1016/S1010-7940(01)00594-2
Trimodality management of malignant pleural mesothelioma.
G. Maggi (2001)
10.1016/S0169-5002(00)00152-5
Surgical approach to pleural diffuse mesothelioma in Japan.
K. Takagi (2001)
10.1097/JTO.0b013e31826915f1
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
FEASIBILITY PHASE OF THE MESOTHELIOMA AND RADICAL SURGERY (MARS) RANDOMISED CONTROLLED TRIAL COMPARING EXTRA-PLEURAL PNEUMONECTOMY (EPP) WITH NO EPP IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA
M. Snee (2011)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1016/J.ATHORACSUR.2007.04.076
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.
D. Rice (2007)
10.1016/S0022-5223(99)70297-7
Pleural space perfusion with cisplatin in the multimodality treatment of malignant mesothelioma: a feasibility and pharmacokinetic study.
G. B. Ratto (1999)
10.1097/JTO.0b013e3182199819
Intensity-Modulated Radiotherapy After Extrapleural Pneumonectomy in the Combined-Modality Treatment of Malignant Pleural Mesothelioma
A. Chi (2011)
10.1016/S0090-3671(10)79654-3
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: A phase II prospective study
D. Jones (2010)
10.1007/s11748-009-0440-2
Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma
K. Okubo (2009)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1016/j.athoracsur.2009.05.036
Trimodality therapy for malignant pleural mesothelioma.
G. Buduhan (2009)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)



This paper is referenced by
10.18632/oncotarget.22062
Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis
Z. Zhao (2017)
10.1002/jso.25726
Adequate nephroprotection reduces renal complications after hyperthermic intrathoracic chemotherapy
T. Markowiak (2019)
10.21037/jtd.2017.04.65
Intrapleural perfusion thermo-chemotherapy for pleural effusion caused by lung carcinoma under VATS.
R. Hu (2017)
10.1016/j.jtcvs.2017.10.070
Diaphragm and lung–preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10‐year experience
M. Ambrogi (2018)
10.1055/A-0934-7806
Expertenempfehlung zur Anwendung der hyperthermen intrathorakalen Chemotherapie (HITOC) in Deutschland
Michael Ried (2020)
A narrative review of current treatment strategies and emerging therapies in malignant pleural mesothelioma
Élise Di Lena (2020)
10.1097/MD.0000000000005532
Effect of hyperthermic intrathoracic chemotherapy (HITHOC) on the malignant pleural effusion
H. Zhou (2017)
10.21037/jtd.2017.10.165
The role of intracavitary therapies in the treatment of malignant pleural mesothelioma.
P. Bertoglio (2018)
10.1007/s00398-018-0260-8
Intraoperative hypertherme intrathorakale Chemotherapie
T. Markowiak (2018)
10.1136/bmjopen-2020-041511
Protocol of a retrospective, multicentre observational study on hyperthermic intrathoracic chemotherapy in Germany
T. Markowiak (2020)
10.1007/s00595-015-1275-3
Current surgical strategies for malignant pleural mesothelioma
T. Takuwa (2015)
10.21037/JTD.2019.02.54
Pathological evaluation of the visceral pleura in the radical pleurectomy/decortication for malignant pleural mesothelioma patients.
M. Kobayashi (2019)
Semantic Scholar Logo Some data provided by SemanticScholar